Carcinoembryonic antigen (CEA)

Similar documents
Cytokeratin 19 (CK19)

Estrogen receptor (ER)

Assessment Run GATA3

Thyroid transcription factor-1 (TTF1) Assessment run

SMH (Myosin, smooth muscle heavy chain)

Assessment Run

Epithelial cell-cell adhesion molecule (Ep-CAM)

Assessment Run NKX3.1 (NKX3.1)

Estrogen receptor (ER)

Sal-like protein 4 (SALL4)

Assessment Run CK19

Assessment Run B HER-2 IHC. HER-2/chr17 ratio**

Lung Anaplastic Lymphoma Kinase (lu-alk)

Estrogen receptor (ER)

Assessment Run B HER2 IHC

Assessment Run B HER2 IHC

Assessment Run C1 2017

Assessment Run C3 2018

Optimization of antibodies, selection, protocols and controls Breast tumours

HER2 ISH (BRISH or FISH)

Breast cancer: Antibody selection, protocol optimzation controls and EQA

Nordic Immunohistochemical Quality Control

External Quality Assessment of melanocytic marker analyses NordiQC experience

NordiQC - update

IHC Stainer platforms. Overview, pros and cons

Assessment Run B HER-2

Quality Assurance in Immunohistochemistry: Experiences from NordiQC

Assessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver

Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital

10 years of NordiQC Why are 30% of labs still getting it wrong?

The impact of proficiency testing on lab immunoassays

NordiQC External Quality Assurance in Immunohistochemistry

External Quality Assessment of Breast Marker Analysis. NordiQC data

Product Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue

Immunohistochemical principles The technical test approach. Pre-analytical parametres

Single and Multiplex Immunohistochemistry

IDH1 R132H/ATRX Immunohistochemical validation

The unknown primary tumour: IHC classification part I, the primary panel - Antibody selection, protocol optimization, controls and EQA

Supplementary Online Content

Immunocytochemistry. Run 119/48. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)

Image analysis in IHC overview, considerations and applications

Immunotherapy in NSCLC Pathologist role

Milestones in Her 2 Testing

Supplementary Appendix

HPV/p16 Analyte Control

The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)

Immunocytochemistry. Run 113/42. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Results you can trust

HistoCyte Laboratories Ltd

ONCO TEAM DIAGNOSTIC

Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Workflow. Connecting the Pieces For Total Patient Care

A National Quality Assurance program for breast immunohistochemistry: an Italian perspective

Immunocytochemistry. Run 120/49. Improving Immunocytochemistry for Over 25 Years Results - Summary Graphs - Pass Rates Best Methods - Selected Images

Product Introduction

Immunohistochemistry. Potential and challenges To be or not to be

# Best Practices for IHC Detection and Interpretation of ER, PR, and HER2 Protein Overexpression in Breast Cancer

The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia

Diagnostic IHC in lung and pleura pathology

Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we

CC01 - Colon Cancer Tissue Microarray

PD-L1 Analyte Control DR

Supplemental Data Table 1 Characteristics of the MHH BC cohort number percent cases histology IDBC ILBC others 6 3 pt status pt1

Classification of the unknown primary tumour: the primary IHC panel

Immunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark

Immunocytochemistry. Results - Summary Graphs - Pass Rates Best Methods - Selected Images. Run 100. Assessment Dates: 3 rd - 22 nd January 2013

CD15 and CEA expression in thymic epithelial neoplasms

Thermo Scientific UltraVision Quanto for Immunohistochemistry The New Generation Micro-Polymer Detection System

Immunohistochemistry on Fluid Specimens: Technical Considerations

VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue

The PAX8 gene is a member of the paired-box family of

Anti-PD-L1 antibody [28-8] ab205921

Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -

Breast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark

Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material

Immunohistochemical Analysis of Hepatocellular and Adenocarcinoma in the Liver: MOC31 Compares Favorably with Other Putative Markers

Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods

Immunohistochemical Evaluation of Necrotic Malignant Melanomas

Liver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle

Digital Pathology and CAP Guidelines

Differential diagnosis of HCC

COMPUTER-AIDED HER-2/neu EVALUATION IN EXTERNAL QUALITY ASSURANCE (EQA) OF BREAST CANCER SCREENING PROGRAMME

Immunohistochemistry in Breast Pathology- Brief Overview of the Technique and Applications in Breast Pathology

Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-

Quality Control/Quality Assurance in Diagnostic Immunohistochemistry

Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use

Stromal CD10 immunohistochemical expression in urothelial carcinoma of urinary bladder and correlation with clinicopathological parameters

TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy

Supplemental figure 1. PDGFRα is expressed dominantly by stromal cells surrounding mammary ducts and alveoli. A) IHC staining of PDGFRα in

Quality in Control. ROS1 Analyte Control. Product Codes: HCL022, HCL023 and HCL024

Supplementary Information

VENTANA PD-L1 (SP142) Assay

Megakaryoblastic Leukemia in a Dog A. Hillström 1, H. Tvedten 1, M. Kiupel 2.

Urothelial Carcinoma (UC)

Review of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo

Immunocytochemistry. Run 106/35. Also In This Issue IN THIS ISSUE

Transcription:

Assessment Run 37 2013 Carcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3-4. Colon adenocarcinoma, 5. Urothelial carcinoma All tissues were fixed in 10% neutral buffered formalin. Criteria for assessing a CEA staining as optimal included: An at least weak to moderate cytoplasmic staining reaction of the majority of the columnar epithelial cells of the appendix with an enhancement of the glycocalyx. A moderate to strong predominantly cytoplasmic staining reaction in virtually all the neoplastic cells in the colon adenocarcinoma no. 3 and in the majority of the neoplastic cells in the colon adenocarcinoma no. 4. An at least weak to moderate predominantly cytoplasmic staining reaction focally of the neoplastic cells in the urothelial carcinoma. No staining in any other cells. Especially no staining reaction of non-specific cross-reacting antigen (NCA = CEACAM6) in leukocytes and biliary glycoprotein (BGP = CEACAM1) in bile canaliculi. 210 laboratories participated in this assessment. 20 laboratories used a polyclonal antibody to CEA cross reacting with NCA and BGP and hence considered inappropriate and not assessed. Of the remaining 190 participants, 59 % achieved a sufficient mark. Antibodies (Abs) used and marks are summarized in table 1. Table 1. Antibodies and assessment marks for CEA, run 37 Concentrated Antibodies 12-140-10 n Vendor Optimal Good Borderline Poor Suff. 1 6 Leica/Novocastra 0 0 1 5 - - CEA31 1 Cell Marque 1 0 0 0 - - mab COL-1 9 4 4 3 1 Thermo/Neomarkers Biocare Invitrogen/Zymed Immunologic Zytomed Suff. OPS 2 13 4 4 0 81 % 100 % mab II-7 89 Dako 12 42 33 2 61 % 93 % mab PARLAM 4 1 BioScience Products AG 0 0 1 0 - - rmab EP216 1 Epitomics 0 1 0 0 - - Ready-To-Use Antibodies B01-94-11-M AM009 CEA31 760-4594 CEA31 236M CEA31 ZM-0062 1 Biogenex 0 0 1 0 - - 12 Ventana/Cell Marque 9 2 1 0 92 % 92 % 1 Cell Marque 1 0 0 0 - - 1 Zhongshan 0 0 1 0 - - COL-1 PM058 1 Biocare 0 1 0 0 - - Nordic Immunohistochemical Quality Control, CEA run 37 2013 Page 1 of 6

II-7 IR/IS622 33 Dako 1 19 13 0 61 % 80 % r II-7 N1586 II-7 PA0004 TF3H8-1 760-2507 2 Dako 0 2 0 0 - - 4 Leica 1 3 0 0 - - 16 Ventana 0 0 0 16 - - Total 190 38 74 55 23 - Proportion 20 % 39 % 29 % 12 % 59 % 1) Proportion of sufficient stains (optimal or good) 2) Proportion of sufficient stains with optimal protocol settings only, see below. Detailed analysis of CEA, Run 37 The following protocol parameters were central to obtain an optimal staining: Concentrated Abs CEA31: The protocol with an optimal result was based on heat induced epitope retrieval (HIER) using CC1 (BenchMark, Ventana) as the retrieval buffer. The mab was diluted 1:400. COL-1: Protocols with optimal results were all based on HIER using either Target Retrieval Solution ph 9 (3-in-1) (TRS ph 9;Dako) (1/1)*, Cell Conditioning 1 (CC1; Ventana) (8/9), Bond Epitope Retrieval Solution 2 (BERS2; Leica) (1/1), BERS 1 (Leica) (1/2), Tris-EDTA/EGTA ph 9 (1/3) or Citrate ph 6 (1/2) as the retrieval buffer. The mab was typically diluted in the range of 1:100-1:500 depending on the total sensitivity of the protocol employed. Using these protocol settings 14 of 14 (100 %) laboratories produced a sufficient staining (optimal or good). * (number of optimal results/number of laboratories using this buffer) II-7: Protocols with optimal results were all based on HIER using either TRS ph 9, 3-in-1 (Dako) (3/17), TRS ph 9 (Dako) (2/8), BERS 2 (Leica) (3/6), Tris-EDTA/EGTA ph 9 (3/10) or EDTA/EGTA ph8 (1/1) as the retrieval buffer. The mab was typically diluted in the range of 1:30-1:320 depending on the total sensitivity of the protocol employed. Using these protocol settings 25 of 27 (93 %) laboratories produced a sufficient staining (optimal or good). In table 2, the overall proportion of optimal staining results using the two most frequently used concentrated Abs on the three most commonly used IHC stainer platforms is summarized. Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective platforms. Table 2. Optimal results for CEA using concentrated antibodies on the 3 main IHC systems* Concentrated antibodies Dako Autostainer Link / Classic Ventana BenchMark XT / Ultra Leica Bond III / Max TRS ph 9.0 TRS ph 6.1 CC1 ph 8.5 CC2 ph 6.0 ER2 ph 9.0 ER1 ph 6.0 20 % 0 % 0 % 50 % 0 % - II-7 5/25* 0/35 0/1 3/6 0/2 100 % 89 % 100 % 50 % - - COL-1 1/1 8/9 1/1 1/2 * Antibody concentration applied as listed above, HIER buffers and detection kits used as provided by the vendors of the respective platforms. ** (number of optimal results/number of laboratories using this buffer) Ready-To-Use Abs (RTU) CEA31 (prod. no. 760-4594, Ventana/Cell Marque): Protocols with optimal results were typically based on HIER using mild or standard Cell Conditioning 1, 16-40 min incubation of the primary Ab and UltraView (760-500) or OptiView (760-700) as detection system. Using these protocol settings 11 of 12 (92 %) laboratories produced an optimal staining. mab II-7 (product.no. IR/IS622, Dako): The protocol with optimal results was based on HIER in PT-Link using TRS ph 9 (3-in-1) (heating time 10 min. at 97 C), 20 min incubation of the primary Ab and EnVision FLEX+ (K8002) as detection system. Using these protocol settings 4 of 5 (80 %) laboratories produced a sufficient staining (optimal or good). Nordic Immunohistochemical Quality Control, CEA run 37 2013 Page 2 of 6

II-7 (product. no. PA0004, Leica/Novocastra): The protocol with optimal result was based on HIER using BERS 2 (Bond, Leica), 15 min of primary Ab and Bond Polymer Refine Detection (DS9800) as detection system. Using these protocol settings 3 of 3 (100 %) laboratories produced a sufficient staining (optimal or good). The most frequent causes of insufficient stainings were: - Less successful primary Ab e.g. all 22 protocols based on the s TF3H8-1 and 12-140-10 gave insufficient results - Inappropriate retrieval - Omission of HIER or use of proteolysis - Less successful performance of the II-7 on the BenchMark IHC platform, Ventana - Too low concentration of the primary Ab In this assessment and concordant to the previous NordiQC assessments of CEA (run 12 2004, run 27 2009) the prevalent features of an insufficient staining were either a generally too weak staining reaction or a false positive staining reaction. A too weak staining reaction was seen in 69 % of the insufficient results (54 out of 78 laboratories). Virtually all laboratories were able to demonstrate CEA in the colon adenocarcinoma no. 3, whereas the colon adenocarcinoma no. 4 and in particular the urothelial carcinoma were much more challenging and required an optimally calibrated protocol. The s II-7, CEA31 and COL-1 could all be used to obtain an optimal staining, although the clones CEA31 and COL-1 provided a higher proportion of optimal results, see table 1. This was seen for both the concentrated formats and the RTU systems based on these clones. Optimal results could be obtained for the II-7 when applied on either the Dako Autostainer system or the Leica Bond system, whereas no optimal results were seen on the Ventana BenchMark system, despite similar protocol settings were used on the three IHC platforms (see table 2). In general, the II-7 showed a significant inferior performance on the Ventana BenchMark system compared to other IHC platforms. If the II-7 was applied in the range of 1:30-320, using HIER in an alkaline buffer CC1 ph 8.5 and performed on the BenchMark platform a sufficient result was obtained by 18 out of 35 laboratories (51 %). In contrast 23 out of 25 protocols (92 %) based on identical settings (Ab titre and HIER in an alkaline buffer) and performed on the Dako Autostainer system were assessed as sufficient and of these 5 were assessed as optimal (20 %). Irrespective of the clone or IHC platform used, inappropriate retrieval, as omission of HIER (n=9 laboratories) or use of proteolytic pre-treatment (n=3 laboratories), gave insufficient results due to weak staining reactions. A false positive reaction was seen in 28 % of the insufficient results (22 out of 78 laboratories). This was related to the following primary Ab clones: The 12-140-10 giving a cross reaction with nonspecific cross-reacting antigen, (NCA; CEACAM6) in leucocytes and the s PARLAM 4 and TF3H8-1 giving a cross reaction with both NCA and biliary glycoprotein (BGP; CEACAM1). All slides showing this positive reaction in either leukocytes and/or bile canaliculi were assessed as insufficient. Controls Appendix, in combination with liver, is the recommended control for CEA. In the appendix the vast majority of the epithelial cells must show an at least weak to moderate cytoplasmic staining reaction. If only the glycocalyx is demonstrated, an inadquate staining in neoplasias with low CEA expression is seen (e.g. as observed in the urothelial carcinoma in this assessment). Liver is recommended as negative control. Bile canaliculi and leucocytes must be negative to verify the specificity of the primary Ab and no cross reaction to BGP or NCA is present. Hepatocytes must be negative to verify a high signal-to-noise ratio and staining due to endogenous biotin or use of a poorly calibrated primary Ab is seen. Effect of external quality assessment This was the 3rd assessment of CEA in NordiQC and a consistent decrease in the pass rate has been seen during these 3 runs as listed in table 3. Table 3. Proportion of sufficient results for CEA in the three NordiQC runs performed Run 12 2004 Run 27 2009 Run 37 2013 Participants, n= 60 123 190 Sufficient results 86 % 75 % 59 % Several parameters contribute to the low pass rate. The consistent use and commercial availability of Abs with a false positive staining (n=23 laboratories) and use of inappropriate retrieval settings (n=12 laboratories) had significant impact, as all these protocols were assessed as insufficient. Nordic Immunohistochemical Quality Control, CEA run 37 2013 Page 3 of 6

In this run for CEA a difference in the pass rates was observed for the laboratories participating in the assessment for the first time compared to the laboratories also participating in the latest assessment, run 27 2009. For the laboratories participating for the first time the pass rate was 49 % (36 of 74 laboratories), whereas the pass rate was 66 % (76 of 116 laboratories) for the laboratories participating in both runs. The tailored recommendations given to the laboratories obtaining an insufficient mark did have a slightly positive impact. In run 27, 28 laboratories were given a tailored recommendation and subsequently submitted a staining in this run. 20 laboratories followed the recommendation of which 12 (60 %) improved to a sufficient result, while 8 did not change their protocol and none of these obtained a sufficient result. Recommendations given to laboratories using the II-7 on the Ventana BenchMark platform were less successful. Conclusive the relatively low pass rate in this run mainly was caused by the increased number of new participants, the extended use of inappropriate protocol settings but also in part of less successful tailored recommendations. Conclusion The s II-7, CEA31 and COL-1 can all be recommended for the demonstration of CEA. The performance of the Abs seems to be influenced by the IHC stainer platform. The II-7 gave an inferior staining performance on the Ventana BenchMark platform compared to other platforms. Irrespective of the clone HIER preferable in an alkaline buffer is mandatory for an optimal staining result. Appendix and liver are the recommended controls for CEA. In the appendix the vast majority of the columnar epithelial cells must show an at least weak to moderate intra-cytoplasmic staining reaction. In the liver no staining must be seen. Fig 1a Optimal CEA staining of the appendix using the CEA31 optimally calibrated and with HIER. A weak to moderate staining reaction is seen in the vast majority of the luminal epithelial cells of the appendix, whereas the glycocalyx show an intense staining reaction. Also compare with Figs. 2a 4a, same protocol. Fig 1b Insufficient CEA staining of the appendix using the mab clone II-7 with a less successful protocol insufficient HIER and too diluted. Only the glycocalyx is distinctively demonstrated, while the cytoplasmic compartment of the epithelial cells is unstained - same field as in Fig. 1a. Also compare with Figs. 2b & 3b, same protocol. Nordic Immunohistochemical Quality Control, CEA run 37 2013 Page 4 of 6

Fig 2a Optimal CEA staining of the colon adenocarcinoma, tissue core no. 4 using same protocol as in Fig. 1a. Virtually all the neoplastic cells show a strong and distinct cytoplasmic staining reaction. No background staining is seen. Fig 2b Insufficient CEA staining of the colon adenocarcinoma, tissue core no. 4 using same protocol as in Fig. 1b. same field as in Fig. 2a. The proportion and intensity of the neoplastic cells demonstrated is significantly reduced compared to the level expected and obtained in Fig. 2a. Fig 3a Optimal CEA staining of the urothelial carcinoma using same protocol as in Figs. 1a & 2a. Focally the neoplastic cells show a strong and distinct staining reaction. No background staining is seen. Fig 3b Insufficient CEA staining of the urothelial carcinoma using same protocol as in Figs. 1b & 2b same field as in Fig. 3a. Only dispersed neoplastic cells show a weak and equivocal staining reaction. Nordic Immunohistochemical Quality Control, CEA run 37 2013 Page 5 of 6

Fig 4a Optimal CEA staining of the liver using same protocol as in Figs. 1a - 3a based on the CEA31. No staining reaction is seen in the Kupffer cells, leucocytes and the bile canaliculi. No background staining is seen. Fig 4b Insufficient CEA staining of the liver using the TF3H8-1. Both the Kupffer cells, leucocytes and bile canaliculi are stained due to a cross reaction of the Ab to NCA (CEACAM6) and BGP (CEACAM1) same field as in Fig. 4a. SN/RR/LE 27-2-2013 Nordic Immunohistochemical Quality Control, CEA run 37 2013 Page 6 of 6